Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

111
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
111
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

164
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
164
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124
Sampling Plans01:23

Sampling Plans

170
Sampling is a crucial step in analytical chemistry, allowing researchers to collect representative data from a large population. Common sampling methods include random, judgmental, systematic, stratified, and cluster sampling.
Random sampling is a method where each member of the population has an equal chance of being selected for the sample. It involves selecting individuals randomly, often using random number generators or lottery-type methods. For example, when analyzing the properties of a...
170
Sample Size Calculation01:19

Sample Size Calculation

3.2K
Knowledge of the sample size is the first requirement to conduct random sampling or an experiment. The sample size is the total number of units, observations, or groups (in some cases) used to get the data to estimate a population parameter. As the name suggests, the sample size is that of the sample drawn from the population and differs from the population size.
The sample size for the given experiment or sampling effort is fundamental to any study design. Sample size decides the number of...
3.2K
Randomized Experiments01:13

Randomized Experiments

6.8K
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection.

The Journal of antimicrobial chemotherapy·2026
Same author

Human infections with avian influenza A(H5) viruses with potential pandemic risk: 1997-2025.

National science review·2026
Same author

Research Waste in Randomised Control Trials of Spinal Manipulative Therapy for Chronic Low Back Pain: Evidence From Trial Sequential Analysis.

European journal of pain (London, England)·2026
Same author

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.

Clinical pharmacology and therapeutics·2026
Same author

Paired and AB/BA Cross-Over Design in Early Phase Clinical Trials: A Closer Look at Within-Subject Variance Bias.

Pharmaceutical statistics·2026
Same author

Clinical testing of drug treatment shortening in patients with TB using PET/CT imaging of lung lesions.

Science translational medicine·2026

Related Experiment Video

Updated: Jun 16, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K

Group sequential designs for clinical trials when the maximum sample size is uncertain.

Amin Yarahmadi1, Lori E Dodd2, Thomas Jaki3,4

  • 1Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.

Statistics in Medicine
|August 21, 2024
PubMed
Summary
This summary is machine-generated.

This study introduces flexible clinical trial designs for emerging diseases, allowing early stopping based on interim analyses to manage sample size uncertainty while controlling statistical error rates.

Keywords:
conditional errorgroup‐sequential stopping boundarysequential probability ratio testspending functionunderrunning analysis

More Related Videos

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

4.4K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.1K

Related Experiment Videos

Last Updated: Jun 16, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K
A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

4.4K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.1K

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Epidemiology

Background:

  • Emerging infectious diseases, like COVID-19, present unique challenges for clinical trial sample size determination due to inherent uncertainties.
  • Traditional fixed sample size designs are often inadequate when disease progression and treatment efficacy are poorly understood.

Purpose of the Study:

  • To develop statistical methods for clinical trials with emerging diseases where advance sample size calculation is difficult.
  • To propose group sequential designs that allow for early trial termination based on interim analyses.

Main Methods:

  • Utilizing group sequential designs to enable interim analyses and potential early stopping.
  • Developing alternative final analysis methods for trials halted early, with or without knowledge of interim results.
  • Addressing the control of type I error rates at nominal levels.

Main Results:

  • Proposed methods ensure type I error rates remain appropriate, neither excessively high nor low.
  • Methods are presented for trials with no maximum sample size, allowing continuation until a stopping boundary or a decision to halt is reached.

Conclusions:

  • Group sequential designs offer a robust framework for clinical trials in emerging disease settings.
  • The proposed methods provide flexibility in trial conduct and analysis, maintaining statistical integrity under uncertainty.